Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are histologically diagnosed with non-small cell clung cancer 2. Patinents who are recurrent or progressive non-small-cell lung cancer 3. More than 20-years olds patients at the time of enrollement 4. ECOG Performance status of 0-2 5. Patients who are possible oral ingestion 6. Patients who are expected to survive more than 3 months from the time of enrollment 7. Patients who provide written informed consent for entry of this trial
Exclusion criteria
Exclusion criteria: 1. Patients with a history of allergy for a component of osimertinib 2. Patients with a history of serious drug allergy 3. Patients with other serious complications 4. Patients who are in pregnancy or intend to get pregnant 5. Patients with orally steroid treatment 6. Patients who are considered to be inappropriate in enrollment of this trial by attending physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal water loss(TEWL), Analysis of stratum corneum components and structure, blood concentration of osimertinib | — |
Countries
Japan
Contacts
Public ContactTomonobu Uchino
University of Shizuoka Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences
Outcome results
None listed